AMLN Pengajuan SEC - Amylin Pharmaceuticals Inc- Laporan Tahunan, Pernyataan Kuasa, Prospektus

Mga Batayang Estadistika

CIK

881464

SEC Filings

All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis. These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Amylin Pharmaceuticals Inc

SEC Filings (Chronological Order)

Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.

August 21, 2012	15-12G	- FORM 15 Form 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 0-19700 Amylin Pharmaceuticals, LLC (Exact name of registrant as spe
August 20, 2012	S-8 POS	- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST EFFECTIVE AMENDMENT TO S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT TO FORM S-8 Post-Effective Amendment to Form S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT TO S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT TO FORM S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	POS AM	- POST EFFECTIVE AMENDMENT NO. 1 TO FORM S-3 Post Effective Amendment No. 1 to Form S-3 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Post-Effective Amendment No. 1 to FORM S-3 REGISTRATION STATEMENT NO. 333-179964 UNDER THE SECURITIES ACT OF 1933 AMYLIN PHARMACEUTICALS, LLC (Exact name of registrant as specified in its charter) Delaware 33-0266089 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Id
August 20, 2012	S-8 POS	- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT TO FORM S-8 Post-Effective Amendment to Form S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT TO FORM S-8 Post-Effective Amendment to Form S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT TO S-8 Post-Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST EFFECTIVE AMENDMENT TO S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT TO FORM S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST EFFECTIVE AMENDMENT TO S-8 Post Effective Amendment to S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT TO FORM S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 20, 2012	S-8 POS	- POST-EFFECTIVE AMENDMENT TO FORM S-8 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Post-Effective Amendment No.
August 13, 2012	8-K	Changes in Control of Registrant, Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Entry into a Material Definitive Agreement, Material Modification to Rights of Security Holders, Unregistered Sales of Equity Securities, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing, Financial Statements and Exhibits, Triggering Events That Accelerate or Increase a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement, Completion of Acquisition or Disposition of Assets UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2012 (August 8, 2012) AMYLIN PHARMACEUTICALS, LLC (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorpo
August 13, 2012	EX-4.2	FIRST SUPPLEMENTAL INDENTURE Supplemental Indenture, dated August 8, 2012 Exhibit 4.2 FIRST SUPPLEMENTAL INDENTURE FIRST SUPPLEMENTAL INDENTURE (“Supplemental Indenture”) dated as of August 8, 2012, between AMYLIN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and THE BANK OF NEW YORK MELLON TRUST COMPANY N.A. (formerly known as The Bank of New York Trust Company, N.A.), a national banking association, as trus
August 13, 2012	EX-3.2	AMENDED AND RESTATED BYLAWS AMYLIN PHARMACEUTICALS, INC. A Delaware Corporation ARTICLE I Fifth Amended and Restated Bylaws Exhibit 3.2 AMENDED AND RESTATED BYLAWS BYLAWS OF AMYLIN PHARMACEUTICALS, INC. A Delaware Corporation ARTICLE I OFFICES Section 1.1 Registered Office. The registered office of the corporation in the State of Delaware shall be located at 2711 Centerville Road, Suite 400, Wilmington Delaware 19808, in the County of New Castle. The name of the corporation’s registere
August 13, 2012	EX-3.1	AMENDED AND RESTATED CERTIFICATE OF INCORPORATION AMYLIN PHARMACEUTICALS, INC. ARTICLE ONE Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF AMYLIN PHARMACEUTICALS, INC. ARTICLE ONE The name of the corporation is Amylin Pharmaceuticals, Inc. (hereinafter called the “Corporation”). ARTICLE TWO The address of the Corporation’s registered office in the state of Delaware is 2711 Centerville Road, Suite 400, Wilmington, New Castle County, Delaware 19808. The name of its regist
August 13, 2012	EX-3.3	CERTIFICATE OF FORMATION AMYLIN PHARMACEUTICALS, LLC Certificate of Formation, dated as of August 8, 2012 Exhibit 3.3 CERTIFICATE OF FORMATION OF AMYLIN PHARMACEUTICALS, LLC This Certificate of Formation is being executed as of August 8, 2012, for the purpose of forming a limited liability company pursuant to the Delaware Limited Liability Company Act, 6 Del. C. §§ 18-101, et seq. The undersigned, being duly authorized to execute and file this Certi
August 13, 2012	EX-3.4	LIMITED LIABILITY COMPANY AGREEMENT AMYLIN PHARMACEUTICALS, LLC Dated as of August 8, 2012 LIMITED LIABILITY COMPANY AGREEMENT AMYLIN PHARMACEUTICALS, LLC Exhibit 3.4 LIMITED LIABILITY COMPANY AGREEMENT OF AMYLIN PHARMACEUTICALS, LLC Dated as of August 8, 2012 LIMITED LIABILITY COMPANY AGREEMENT OF AMYLIN PHARMACEUTICALS, LLC This Limited Liability Company Agreement (this “Agreement”) of Amylin Pharmaceuticals, LLC is entered into by BMS Holdco, Inc., a Delaware corporation, as sole member (the “Managing Member”). The Managing Member hereby forms a
August 10, 2012	SC 13G/A	AMLN / Amylin Pharmaceuticals Inc / WELLINGTON MANAGEMENT GROUP LLP - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 9)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032346108 (CUSIP Number) July 31, 2012 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi
August 8, 2012	SC TO-T/A	- AMENDMENT NO.6 TO THE SCHEDULE TO Amendment No.6 to the Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 6 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 P
August 8, 2012	SC 14D9/A	- AMENDMENT NO. 7 TO SCHEDULE 14D-9 Amendment No. 7 to Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 7 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share
August 8, 2012	EX-99.A.5.P	Bristol-Myers Squibb Announces Successful Completion of Cash Tender Offer for Shares of Amylin Pharmaceuticals, Inc. Press Release issued by Bristol-Myers Squibb Company, dated August 8, 2012 Exhibit EXA5P Bristol-Myers Squibb Announces Successful Completion of Cash Tender Offer for Shares of Amylin Pharmaceuticals, Inc.
August 8, 2012	SC 13D/A	AMLN / Amylin Pharmaceuticals Inc / ICAHN CARL C Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 15)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $.001 (Title of Class of Securities) 032346108 (CUSIP Number) Keith Schaitkin, Esq. Icahn Capital LP 767 Fifth Avenue, 47th Floor New York, New York 10153 (212) 702-4300 (Name, Address and Telephon
August 8, 2012	15-12G	- FORM 15 Form 15 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File No.: 000-19700 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as sp
August 3, 2012	EX-10.2	SIXTH AMENDMENT TO EXENATIDE MANUFACTURING AGREEMENT Exhibit 10.2 *** Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R Sections 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended. SIXTH AMENDMENT TO EXENATIDE MANUFACTURING AGREEMENT THIS SIXTH AMENDMENT to the Exenatide Manufacturing Agreement (the “Sixth Amendment”) originally made and entered into as of
August 3, 2012	EX-10.1	AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT Exhibit 10.1 CONFIDENTIAL *** Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R Sections 200.80(b)(4) and Rule 406 of the Securities Act of 1933, as amended. AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT This AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT (the “Amendment”) is entered into as of April 17, 2012 (the “Amendment Effecti
August 3, 2012	10-Q	Quarterly Report - Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS, INC.
August 1, 2012	SC TO-T/A	- AMENDMENT NO. 5 TO SCHEDULE TO SC TO-T/A 1 d389345dsctota.htm AMENDMENT NO. 5 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 5 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMM
August 1, 2012	SC 14D9/A	- AMENDMENT NO. 6 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 6 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 03
August 1, 2012	EX-99.A.5.O	Bristol-Myers Squibb Announces Expiration of the Hart-Scott-Rodino Waiting Period for Acquisition of Amylin Pharmaceuticals, Inc. PRESS RELEASE ISSUED BY BRISTOL-MYERS SQUIBB COMPANY, DATED AUGUST 1, 2012 Exhibit 99.
July 30, 2012	SC 13G	AMLN / Amylin Pharmaceuticals Inc / ADAGE CAPITAL PARTNERS GP, L.L.C. - AMYLIN PHARMACEUTICALS, INC. Passive Investment SC 13G 1 p12-1419sc13g.htm AMYLIN PHARMACEUTICALS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2(b) (Amendment No. )* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $0.001 Par Value (Title of Class of Securi
July 27, 2012	EX-99.(A)(5)(M)	BRISTOL-MYERS SQUIBB PRICES $2.0 BILLION OF SENIOR NOTES Press Release issued by Bristol-Myers Squibb Company, dated July 26, 2012 BRISTOL-MYERS SQUIBB PRICES $2.
July 27, 2012	EX-99.(A)(5)(L)	IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE x IN RE AMYLIN PHARMACEUTICALS, INC. SHAREHOLDERS LITIGATION : : : : CONSOLIDATED C.A. No. 7673-CS x MEMORANDUM OF UNDERSTANDING EX-99.(A)(5)(L) 2 d386485dex99a5l.htm MEMORANDUM OF UNDERSTANDING Exhibit (a)(5)(L) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE x IN RE AMYLIN PHARMACEUTICALS, INC. SHAREHOLDERS LITIGATION : : : : CONSOLIDATED C.A. No. 7673-CS x MEMORANDUM OF UNDERSTANDING WHEREAS, this Memorandum of Understanding (“MOU”) is entered into as of July 27, 2012, by and among the parties to the action captioned I
July 27, 2012	SC 14D9/A	- AMENDMENT NO. 4 TO SCHEDULE 14D-9 SC 14D9/A 1 d386485dsc14d9a.htm AMENDMENT NO. 4 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 4 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common S
July 27, 2012	SC 14D9/A	- AMENDMENT NO. 5 TO SCHEDULE 14D-9 AMENDMENT NO. 5 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 5 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share
July 27, 2012	SC TO-T/A	- AMENDMENT NO. 4 TO SCHEDULE TO Amendment No. 4 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 4 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 PER
July 23, 2012	EX-99.(A)(5)(K)	UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA SUSHA HALBERSTAM, Individually and on ) Case No.: ‘12CV1787 LAB JMA Behalf of All Others Similarly Situated, ) CLASS ACTION COMPLAINT FOR VIOLATION OF THE FEDERAL SECURITIES LAWS JURY TRIAL Class Action Complaint dated July 20, 2012 Exhibit (a)(5)(K) Case 3:12-cv-01787-LAB-JMA Document 1 Filed 07/20/12 Page 1 of 42 WEISS & LURIE LEIGH A.
July 23, 2012	SC TO-T/A	- AMENDMENT NO. 3 TO SCHEDULE TO AMENDMENT NO. 3 TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 3 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 PER
July 23, 2012	EX-99.(A)(5)(L)	UNITED STATES DISTRICT COURT FOR THE SOUTHERN DISTRICT OF CALIFORNIA PETER DOUCET, individually and on behalf ) of all others similarly situated, ) ) Plaintiff, ) CASE NO. ) v. ) ) CLASS ACTION COMPLAINT DANIEL BRADBURY, PAULO COSTA, ) JAY SKYLER, JO Exhibit (a)(5)(L) BRAMSON, PLUTZIK, MAHLER & BIRKHAEUSER, LLP Alan R. Plutzik (State Bar No. 077785) Michael S. Strimling (State Bar No. 96135) 2125 Oak Grove Road, Suite 120 Walnut Creek, CA 94598 Tel: (925) 945-0200 Fax: (925) 945-8792 LEVI & KORSINSKY LLP Joseph Levi (to be admitted pro hac vice) W. Scott Holleman (to be admitted pro hac vice) 30 Broad Street, 24th Floor New York, New York 1000
July 23, 2012	SC 14D9/A	- AMENDMENT NO. 3 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 3 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 03
July 18, 2012	SC TO-T/A	- AMENDMENT NO. 2 TO SCHEDULE TO Amendment No. 2 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 2 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 PER
July 18, 2012	EX-99.(A)(5)(H)	IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MAXINE PHILLIPS, Individually and on Behalf ) of All Others Similarly Situated, ) ) Plaintiff, ) ) v. ) C.A. No. 7673-CS ) AMYLIN PHARMACEUTICALS, INC., PAULO ) F. COSTA, ADRIAN ADAMS, TERESA BECK, ) EX-99.(A)(5)(H) 2 d377624dex99a5h.htm STIPULATED ORDER OF CLASS CERTIFICATION AND CASE MANAGEMENT DATED JULY 10, 2012 Exhibit (a)(5)(H) GRANTED IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MAXINE PHILLIPS, Individually and on Behalf ) of All Others Similarly Situated, ) ) Plaintiff, ) ) v. ) C.A. No. 7673-CS ) AMYLIN PHARMACEUTICALS, INC., PAULO ) F. COSTA, ADRIAN ADAMS, TERESA BECK, ) M. KAT
July 18, 2012	SC 14D9/A	- AMENDMENT NO. 2 TO SCHEDULE 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 2 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (Title of Class of Securities) 03
July 18, 2012	EX-99.(A)(5)(I)	IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MAXINE PHILLIPS, Individually and on Behalf of All ) Others Similarly Situated, ) ) Plaintiff, ) C.A. No. 7673-CS ) v. ) ) AMYLIN PHARMACEUTICALS, INC., PAULO F. ) COSTA, ADRIAN ADAMS, TERESA BECK, M. Amended Class Action Complaint dated July 12, 2012 Exhibit (a)(5)(I) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MAXINE PHILLIPS, Individually and on Behalf of All ) Others Similarly Situated, ) ) Plaintiff, ) C.
July 18, 2012	EX-99.(A)(5)(J)	FILED CIVIL BUSINESS OFFICE 8 CENTRAL DIVISION 12 JUL 10 PM 2:04 CLERK-SUPERIOR COURT SAN DIEGO COUNTY, CA Class Action Complaint dated July 10, 2012 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 Exhibit (a)(5)(J) FILED CIVIL BUSINESS OFFICE 8 CENTRAL DIVISION 12 JUL 10 PM 2:04 CLERK-SUPERIOR COURT SAN DIEGO COUNTY, CA Evan J.
July 17, 2012	SC 14D9/A	- AMENDMENT NO. 1 SCHEDULE 14D-9 Amendment No. 1 Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Amendment No. 1 to SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001 per share (T
July 17, 2012	EX-99.(A)(5)(F)	2 All terms of any Offer to Purchase, Plan Documents, policies supersede the information included here. Nothing here is to be considered advice or direction. EX-99.(A)(5)(F) 3 d380894dex99a5f.htm AMYLIN INTEGRATION - FREQUENTLY ASKED QUESTIONS (FAQS) Exhibit (a)(5)(F) Amylin Integration – Frequently Asked Questions (FAQs) Table of Contents Click on the section below to go directly to that section. Tender Offer Leadership, Structure, Sites, Timing Integration Compensation and Benefits Miscellaneous Please review this document for answers to your frequen
July 17, 2012	SC TO-T/A	- AMENDMENT NO. 1 TO SCHEDULE TO Amendment No. 1 to Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMENDMENT NO. 1 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 PER
July 17, 2012	EX-99.(A)(5)(E)	Town Hall Meeting Bob: So to get on to the main business here today. The BMS management team wanted to come visit us immediately the acquisition was announced, however, we were in the middle of an FDA inspection, so thankfully they said, “Yeah, we’ll Town Hall Meeting Exhibit (a)(5)(E) Town Hall Meeting Bob: So to get on to the main business here today.
July 10, 2012	EX-99.(A)(1)(G)	Notice of Offer to Purchase for Cash All Outstanding Shares of Common Stock AMYLIN PHARMACEUTICALS, INC. $31.00 Net Per Share B&R ACQUISITION COMPANY, a wholly-owned subsidiary of BRISTOL-MYERS SQUIBB COMPANY Summary Advertisement as published in the Wall Street Journal Exhibit No. (a)(1)(G) This announcement is neither an offer to purchase nor a solicitation of an offer to sell Shares (as defined below). The Offer (as defined below) is made solely by the Offer to Purchase (as defined below), dated July 10, 2012, and the related Letter of Transmittal (as defined below) and any amendments or supplements
July 10, 2012	EX-99.(A)(1)(E)	Offer To Purchase For Cash All Outstanding of Shares of Common Stock AMYLIN PHARMACEUTICALS, INC., a Delaware corporation $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 B&R ACQUISITION COMPANY, a Delaware corporation and a Exhibit No. (a)(1)(E) Offer To Purchase For Cash All Outstanding of Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC., a Delaware corporation at $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 by B&R ACQUISITION COMPANY, a Delaware corporation and a wholly-owned subsidiary of BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation. THE OFFER AND WITHDRAWAL RIGHTS WILL
July 10, 2012	EX-99.(A)(1)(D)	Offer To Purchase For Cash All Outstanding Shares of Common Stock AMYLIN PHARMACEUTICALS, INC., a Delaware corporation $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 B&R ACQUISITION COMPANY, a Delaware corporation and a wh Exhibit No. (a)(1)(D) Offer To Purchase For Cash All Outstanding Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC., a Delaware corporation at $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 by B&R ACQUISITION COMPANY, a Delaware corporation and a wholly-owned subsidiary of BRISTOL-MYERS SQUIBB COMPANY, a Delaware corporation. THE OFFER AND WITHDRAWAL RIGHTS WILL EXP
July 10, 2012	EX-99.(A)(1)(B)	LETTER OF TRANSMITTAL To Tender Shares of Common Stock AMYLIN PHARMACEUTICALS, INC., a Delaware corporation $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 B&R ACQUISITION COMPANY, a Delaware corporation and a wholly-owned EX-99.(A)(1)(B) 3 d376793dex99a1b.htm LETTER OF TRANSMITTAL Exhibit No. (a)(1)(B) LETTER OF TRANSMITTAL To Tender Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC., a Delaware corporation at $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 by B&R ACQUISITION COMPANY, a Delaware corporation and a wholly-owned subsidiary of BRISTOL-MYERS SQUIBB COMPANY, a Delaware corp
July 10, 2012	EX-99.(A)(1)(A)	Offer to Purchase for Cash All Outstanding Shares of Common Stock AMYLIN PHARMACEUTICALS, INC. $31.00 Net Per Share B&R ACQUISITION COMPANY, a wholly–owned subsidiary of BRISTOL–MYERS SQUIBB COMPANY Offer to Purchase Table of Contents Exhibit (a)(1)(A) Offer to Purchase for Cash All Outstanding Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC.
July 10, 2012	EX-99.(A)(1)(I)	July 10, 2012 EX-99.(A)(1)(I) 2 d379036dex99a1i.htm LETTER Exhibit (a)(1)(I) July 10, 2012 Dear Amylin Stockholders: We are pleased to report that Amylin Pharmaceuticals, Inc. (the “Company”) has entered into an Agreement and Plan of Merger, dated June 29, 2012 (the “Merger Agreement”), with Bristol-Myers Squibb Company (“Parent”) and B&R Acquisition Company (“Merger Sub”), a wholly-owned subsidiary of Parent,
July 10, 2012	EX-99.(A)(5)(C)	IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MAXINE PHILLIPS, Individually and on Behalf of All ) Others Similarly Situated, ) ) Plaintiff, ) C.A. No. ) v. ) ) AMYLIN PHARMACEUTICALS, INC., PAULO F. ) COSTA, ADRIAN ADAMS, TERESA BECK, M. ) KATHL Class Action Complaint dated July 3, 2012 Exhibit (a)(5)(C) IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE MAXINE PHILLIPS, Individually and on Behalf of All ) Others Similarly Situated, ) ) Plaintiff, ) C.
July 10, 2012	SC TO-T	- SCHEDULE TO SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(d)(1) OR 13(e)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) BRISTOL-MYERS SQUIBB COMPANY (Offeror) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Securities
July 10, 2012	EX-99.(A)(5)(D)	SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF SAN DIEGO DOUGLAS PETERSON, on Behalf of ) Case No. 37-2012-00100092-CU-BT-CTL Himself and All Others Similarly Situated, ) ) CLASS ACTION Plaintiff, ) V. ) ) COMPLAINT BASED UPON SELF-DEALING AMYLI Exhibit(a)(5)(D) ROBBINS UMEDA LLP BRIAN J. ROBBINS (190264) STEPHEN J. ODDO (174828) ARSHAN AMIRI (246874) EDWARD B. GERARD (248053) JUSTIN D. RIEGER (257321) 600 B Street, Suite 1900 San Diego, CA 92101 Telephone: (619) 525-3990 Facsimile: (619) 525-3991 Attorneys for Plaintiff [Additional Counsel on Signature Page] SUPERIOR COURT OF THE STATE OF CALIFORNIA COUNTY OF SAN DIEGO DOUGLAS PETERSON,
July 10, 2012	EX-99.(A)(5)(D)	EFiled: Jul 9 2012 8:10PM Transaction ID 45230660 Case No. 7682- Exhibit (a)(5)(D) EFiled: Jul 9 2012 8:10PM Transaction ID 45230660 Case No. 7682- IN THE COURT OF CHANCERY OF THE STATE OF DELAWARE SUSHA HALBERSTAM On Behalf of Herself and All Other Similarly Situated, Plaintiff, V. AMYLIN PHARMACEUTICALS, INC., DANIEL M. BRADBURY, PAULO F. COSTA, ADRIAN ADAMS, TERESA BECK, M. KATHLEEN BEHRENS, ALEXANDER J. DENNER, KARIN EASTHAM, JAMES R. GAVIN III, JAY S. SKYL
July 10, 2012	SC 14D9	- SCHEDULE 14D-9 SC 14D9 1 d379036dsc14d9.htm SCHEDULE 14D-9 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 Solicitation/Recommendation Statement under Section 14(d)(4) of the Securities Exchange Act of 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) Common Stock, par value $0.001
July 10, 2012	EX-99.(A)(1)(C)	NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock AMYLIN PHARMACEUTICALS, INC., a Delaware corporation $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 B&R ACQUISITION COMPANY, a Delaware corporation and a w EX-99.(A)(1)(C) 4 d376793dex99a1c.htm NOTICE OF GUARANTEED DELIVERY Exhibit No. (a)(1)(C) NOTICE OF GUARANTEED DELIVERY For Tender of Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC., a Delaware corporation at $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 by B&R ACQUISITION COMPANY, a Delaware corporation and a wholly-owned subsidiary of BRISTOL-MYERS SQUIBB COMP
July 10, 2012	EX-99.(A)(1)(F)	INSTRUCTION FORM With Respect to the Offer To Purchase For Cash All Outstanding of Shares of Common Stock AMYLIN PHARMACEUTICALS, INC., a Delaware corporation $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 B&R ACQUISITION Instruction Form to be Used with the Letter of Transmittal Exhibit No. (a)(1)(F) INSTRUCTION FORM With Respect to the Offer To Purchase For Cash All Outstanding of Shares of Common Stock of AMYLIN PHARMACEUTICALS, INC., a Delaware corporation at $31.00 NET PER SHARE Pursuant to the Offer to Purchase dated July 10, 2012 by B&R ACQUISITION COMPANY, a Delaware corporation and a wholly-owned subsidiar
July 10, 2012	EX-99.(A)(5)(B)	Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals, Inc. Press Release Exhibit No. (a)(5)(B) Bristol-Myers Squibb Begins Tender Offer to Acquire Amylin Pharmaceuticals, Inc. (NEW YORK & PRINCETON, NJ, July 10, 2012) — Bristol-Myers Squibb Company (NYSE: BMY) is commencing today, through its wholly owned subsidiary B&R Acquisition Company, a cash tender offer to purchase all outstanding shares of common stock of Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN
July 10, 2012	EX-99.(D)(2)	TENDER AND SUPPORT AGREEMENT Tender and Support Agreement Exhibit (d)(2) EXECUTION VERSION TENDER AND SUPPORT AGREEMENT This TENDER AND SUPPORT AGREEMENT (this “Agreement”), dated as of June 29, 2012, is by and among Bristol-Myers Squibb Company, a Delaware corporation (“Parent”), B&R Acquisition Company, a Delaware corporation and a wholly owned subsidiary of Parent (“Sub”), Amylin Pharmaceuticals, Inc.
July 6, 2012	EX-99.1	Town Hall Meeting Dan: So everybody can hear. All right, well good morning. Very exciting day here for Amylin. As I know that you’re all aware, we announced on Friday, late Friday night, after a very long day, we announced that we are entering into a Transcript of Town Hall Meeting Exhibit 99.1 Town Hall Meeting Dan: So everybody can hear. All right, well good morning. Very exciting day here for Amylin. As I know that you’re all aware, we announced on Friday, late Friday night, after a very long day, we announced that we are entering into a definitive merger agreement with Bristol-Myers Squibb. It’s actually part of a two-part process in that
July 6, 2012	EX-99.2	Town Hall Meeting Dan: Okay, well, welcome back. Good to see everybody again. I’m absolutely delighted to introduce to you today colleagues now from Bristol-Myers Squibb and AstraZeneca. And I’d firstly like to introduce Giovanni Caforio. Giovanni is Transcript of Town Hall Meeting Exhibit 99.2 Town Hall Meeting Dan: Okay, well, welcome back. Good to see everybody again. I’m absolutely delighted to introduce to you today colleagues now from Bristol-Myers Squibb and AstraZeneca. And I’d firstly like to introduce Giovanni Caforio. Giovanni is the President of U.S. Pharmaceuticals for Bristol-Myers Squibb. And sitting right next to him is Rich Fa
July 6, 2012	SC14D9C	- SCHEDULE 14D-9 Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Sec
July 3, 2012	SC TO-C	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2012 (June 29, 2012) AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of I
July 3, 2012	EX-2.1	AGREEMENT AND PLAN OF MERGER BY AND AMONG BRISTOL-MYERS SQUIBB COMPANY, B&R ACQUISITION COMPANY AMYLIN PHARMACEUTICALS, INC. DATED AS OF JUNE 29, 2012 TABLE OF CONTENTS Page INDEX OF DEFINED TERMS iii Article I THE OFFER 2 1.1 The Offer 2 1.2 Company Agreement and Plan of Merger Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG BRISTOL-MYERS SQUIBB COMPANY, B&R ACQUISITION COMPANY AND AMYLIN PHARMACEUTICALS, INC. DATED AS OF JUNE 29, 2012 TABLE OF CONTENTS Page INDEX OF DEFINED TERMS iii Article I THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 1.3 Directors 5 1.4 Top-Up Option 7 Article II THE MERGER 8 2.1 The Merger 8
July 3, 2012	EX-2.1	AGREEMENT AND PLAN OF MERGER BY AND AMONG BRISTOL-MYERS SQUIBB COMPANY, B&R ACQUISITION COMPANY AMYLIN PHARMACEUTICALS, INC. DATED AS OF JUNE 29, 2012 TABLE OF CONTENTS Page INDEX OF DEFINED TERMS iii Article I THE OFFER 2 1.1 The Offer 2 1.2 Company Agreement and Plan of Merger Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG BRISTOL-MYERS SQUIBB COMPANY, B&R ACQUISITION COMPANY AND AMYLIN PHARMACEUTICALS, INC. DATED AS OF JUNE 29, 2012 TABLE OF CONTENTS Page INDEX OF DEFINED TERMS iii Article I THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 1.3 Directors 5 1.4 Top-Up Option 7 Article II THE MERGER 8 2.1 The Merger 8
July 3, 2012	EX-10.1	ASSUMPTION AGREEMENT Assumption Agreement Exhibit 10.1 ASSUMPTION AGREEMENT This ASSUMPTION AGREEMENT (this “Assumption Agreement”) is entered into as of June 29, 2012 (the “Effective Date”) by and between Amylin Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Amylin”) and Bristol-Myers Squibb Company, a Delaware Corporation (the “Company”). Amylin and the Company
July 3, 2012	EX-10.1	ASSUMPTION AGREEMENT Assumption Agreement Exhibit 10.1 ASSUMPTION AGREEMENT This ASSUMPTION AGREEMENT (this “Assumption Agreement”) is entered into as of June 29, 2012 (the “Effective Date”) by and between Amylin Pharmaceuticals, Inc., a corporation organized and existing under the laws of the State of Delaware (“Amylin”) and Bristol-Myers Squibb Company, a Delaware Corporation (the “Company”). Amylin and the Company
July 3, 2012	EX-2.1	AGREEMENT AND PLAN OF MERGER BY AND AMONG BRISTOL-MYERS SQUIBB COMPANY, B&R ACQUISITION COMPANY AMYLIN PHARMACEUTICALS, INC. DATED AS OF JUNE 29, 2012 TABLE OF CONTENTS Page INDEX OF DEFINED TERMS iii Article I THE OFFER 2 1.1 The Offer 2 1.2 Company Agreement and Plan of Merger Exhibit 2.1 EXECUTION VERSION AGREEMENT AND PLAN OF MERGER BY AND AMONG BRISTOL-MYERS SQUIBB COMPANY, B&R ACQUISITION COMPANY AND AMYLIN PHARMACEUTICALS, INC. DATED AS OF JUNE 29, 2012 TABLE OF CONTENTS Page INDEX OF DEFINED TERMS iii Article I THE OFFER 2 1.1 The Offer 2 1.2 Company Actions 4 1.3 Directors 5 1.4 Top-Up Option 7 Article II THE MERGER 8 2.1 The Merger 8
July 3, 2012	8-K	Entry into a Material Definitive Agreement, Financial Statements and Exhibits Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 2, 2012 (June 29, 2012) AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of I
July 3, 2012	EX-99.1	Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceuticals EX-99.1 3 d376142dex991.htm JOINT PRESS RELEASE Exhibit 99.1 Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceuticals • Strengthens Leadership Position of Successful Alliance in Growing Area of High Unmet Medical Need • Complements Current Portfolio Creating a More Comprehensive Disease Management Platform with the Addition
July 3, 2012	SC TO-C	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act Of 1934 Date of Report (Date of earliest event reported): July 2, 2012 (June 29, 2012) BRISTOL-MYERS SQUIBB COMPANY (Exact Name of Registrant as Specified in its Charter) Delaware 1-1136 22-079-0350 (State or Other Jurisdiction of I
July 2, 2012	EX-99.1	Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceuticals EX-99.1 2 d375971dex991.htm JOINT PRESS RELEASE Exhibit 99.1 Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceuticals • Strengthens Leadership Position of Successful Alliance in Growing Area of High Unmet Medical Need • Complements Current Portfolio Creating a More Comprehensive Disease Management Platform with the Addition
July 2, 2012	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commissio
July 2, 2012	SC TO-C	- SCHEDULE TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Offeror) (Names of Filing Persons (identifying status as offer
July 2, 2012	SC14D9C	- SCHEDULE 14D-9 Schedule 14D-9 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14D-9 (Rule 14d-101) SOLICITATION/RECOMMENDATION STATEMENT UNDER SECTION 14(D)(4) OF THE SECURITIES EXCHANGE ACT OF 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company) AMYLIN PHARMACEUTICALS, INC. (Names of Persons Filing Statement) COMMON STOCK, PAR VALUE $0.001 PER SHARE (Title of Class of Sec
July 2, 2012	EX-99.1	Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceuticals Joint Press Release Exhibit 99.1 Bristol-Myers Squibb and AstraZeneca Expand Diabetes Alliance Through Bristol-Myers Squibb’s Acquisition of Amylin Pharmaceuticals • Strengthens Leadership Position of Successful Alliance in Growing Area of High Unmet Medical Need • Complements Current Portfolio Creating a More Comprehensive Disease Management Platform with the Addition of Novel GLP-1 Agonist Franc
July 2, 2012	SC TO-C	- FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (
July 2, 2012	SC TO-C	- SCHEDULE TO Schedule TO UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE TO TENDER OFFER STATEMENT UNDER SECTION 14(D)(1) OR 13(E)(1) OF THE SECURITIES EXCHANGE ACT OF 1934 AMYLIN PHARMACEUTICALS, INC. (Name of Subject Company (Issuer)) B&R ACQUISITION COMPANY (Offeror) A Wholly Owned Subsidiary of BRISTOL-MYERS SQUIBB COMPANY (Offeror) (Names of Filing Persons (identifying sta
June 18, 2012	8-K	Other Events - FORM 8-K FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): June 18, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (
June 5, 2012	8-K	Other Events 8-K 1 d363338d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 5, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction
May 16, 2012	EX-99.2	AMYLIN PHARMACEUTICALS, INC. 2001 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED Employee Stock Purchase Plan. Exhibit 99.2 AMYLIN PHARMACEUTICALS, INC. 2001 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED 1. PURPOSE. (a) The purpose of the Plan is to provide a means by which Employees of the Company and certain designated Related Corporations may be given an opportunity to purchase shares of the Common Stock of the Company. (b) The Company, by means of the Plan, seeks to retain the
May 16, 2012	EX-99.1	AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN (AMENDED BY THE BOARD MARCH 6, 2012) (APPROVED BY THE STOCKHOLDERS MAY 15, 2012) Equity Incentive Plan. Exhibit 99.1 AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN (AMENDED BY THE BOARD MARCH 6, 2012) (APPROVED BY THE STOCKHOLDERS MAY 15, 2012) 1. GENERAL. (a) The Plan is intended as the successor to and continuation of the Amylin Pharmaceuticals, Inc. 2001 Equity Incentive Plan (the “Prior Plan”). Following the Effective Date, no additional stock awards shall be gran
May 16, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 15, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commission
May 15, 2012	DEFA14A	- DEFINITIVE ADDITIONAL MATERIALS DEFA14A 1 d353148ddefa14a.htm DEFINITIVE ADDITIONAL MATERIALS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of
May 15, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (C
May 7, 2012	10-Q	Quarterly Report - FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2012 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS, INC
May 7, 2012	EX-10.1	MASTER SERVICE AGREEMENT ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. §§ 200.80(b)(4) Exhibit 10.1 MASTER SERVICE AGREEMENT This Master Service Agreement (this “Agreement”) made as of February 1, 2012 and effective as of November 7, 2011 (the “Effective Date”) by and between Ventiv Commercial Services, LLC, a New Jersey limited liability company with offices at 500 Atrium Drive, So
April 26, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 26, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation)
April 26, 2012	EX-99.1	AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS BYDUREON, first and only weekly treatment for type 2 diabetes, launched in the U.S. Press release Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Investors – Christine Everett-Zedelmayer Phone: (858) 458-8517 Email: [email protected] Media – Alice Izzo Phone: (858) 232-9072 Email: [email protected] AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER 2012 FINANCIAL RESULTS BYDUREON, first and only weekly treatment for type 2 diabetes, launched in the U.S. San Diego, CA – Apri
April 25, 2012	SC 13D/A	AMLN / Amylin Pharmaceuticals Inc / ICAHN CARL C Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 14)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $.001 (Title of Class of Securities) 032346108 (CUSIP Number) Keith Schaitkin, Esq. Icahn Capital LP 767 Fifth Avenue, 47th Floor New York, New York 10153 (212) 702-4300 (Name, Address and Telephon
April 12, 2012	DEF 14A	- DEFINITIVE PROXY STATEMENT Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 9, 2012	SC 13D/A	AMLN / Amylin Pharmaceuticals Inc / ICAHN CARL C Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 13)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $.001 (Title of Class of Securities) 032346108 (CUSIP Number) Keith Schaitkin, Esq. Icahn Capital LP 767 Fifth Avenue, 47th Floor New York, New York 10153 (212) 702-4300 (Name, Address and Telephon
April 4, 2012	SC 13D/A	AMLN / Amylin Pharmaceuticals Inc / ICAHN CARL C Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 12)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock, Par Value $.001 (Title of Class of Securities) 032346108 (CUSIP Number) Keith Schaitkin, Esq. Icahn Capital LP 767 Fifth Avenue, 47th Floor New York, New York 10153 (212) 702-4300 (Name, Address and Telephon
March 9, 2012	EX-1.1	13,000,000 Amylin Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT Underwriting Agreement Exhibit 1.1 13,000,000 Amylin Pharmaceuticals, Inc. Common Stock UNDERWRITING AGREEMENT March, 7, 2012 CREDIT SUISSE SECURITIES (USA) LLC, Eleven Madison Avenue, New York, N.Y. 10010-3629 Dear Sirs: 1. Introductory. Amylin Pharmaceuticals, Inc., a Delaware corporation (“Company”), agrees with Credit Suisse Securities (USA) LLC (“Credit Suisse”) to issue and sell 13,000,000 s
March 9, 2012	424B5	CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Unit(1) Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-179964 CALCULATION OF REGISTRATION FEE Title of each Class of Securities to be Registered Amount to be Registered Proposed Maximum Offering Price Per Unit(1) Proposed Maximum Aggregate Offering Price(1) Amount of Registration Fee(2) Common Stock, par value $0.001 per share 14,950,000 $16.01 $239,349,500 $27,430 (1) Estimated s
March 9, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (
March 9, 2012	EX-99.1	AMYLIN PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK Press Release Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Investors – Christine Everett-Zedelmayer Phone: (858) 458-8517 Email: [email protected] Media – Alice Izzo Phone: (858) 642-7272 Email: [email protected] AMYLIN PHARMACEUTICALS ANNOUNCES PUBLIC OFFERING OF COMMON STOCK SAN DIEGO, March 7, 2012 – Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that it is offering
March 9, 2012	EX-99.2	AMYLIN PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK Press Release Exhibit 99.2 FOR IMMEDIATE RELEASE Contacts: Investors – Christine Everett-Zedelmayer Phone: (858) 458-8517 Email: [email protected] Media – Alice Izzo Phone: (858) 642-7272 Email: [email protected] AMYLIN PHARMACEUTICALS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK SAN DIEGO, March 8, 2012 – Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced the prici
March 7, 2012	S-3ASR	- FORM S-3 S-3ASR 1 d309792ds3asr.htm FORM S-3 Table of Contents As filed with the Securities and Exchange Commission on March 7, 2012 Registration No. 333– SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S–3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 33-0266089 (State of Incorporation) (I
March 7, 2012	424B5	SUBJECT TO COMPLETION, DATED MARCH 7, 2012 PRELIMINARY PROSPECTUS SUPPLEMENT TO PROSPECTUS DATED MARCH 7, 2012 13,000,000 Shares Common Stock Table of Contents The Information in this preliminary prospectus supplement is not complete and may be changed.
March 6, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 6, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (
February 22, 2012	EX-10.45	SECOND AMENDMENT TO THE COMMERCIAL SUPPLY AGREEMENT Second Amendment to Commercial Supply Agreement EXHIBIT 10.45 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. SECOND AMENDMENT TO THE COMMERCIAL SUPPLY AGREEMENT This Second Amendment to the Commercial Supply Agreement dated February 14, 2005 (this “Second Amendment”), is effecti
February 22, 2012	EX-4.8	SUBSIDIARY GUARANTEE AGREEMENT Subsidiary Guarantee Agreement Exhibit 4.8 EXECUTION VERSION SUBSIDIARY GUARANTEE AGREEMENT THIS SUBSIDIARY GUARANTEE AGREEMENT (this “Agreement”) is made as of this 7th day of November, 2011 (the “Effective Date”), by Amylin Ohio LLC, a Delaware limited liability company (“Amylin Ohio”), and each of the other parties hereto as an Additional Guarantor (as herein defined) (collectively with Amylin
February 22, 2012	EX-10.44	THIRD AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT AMYLIN PHARMACEUTICALS, INC. WOCKHARDT UK (HOLDINGS) LTD. Third Amendment to Amended and Restated Commercial Supply Agreement EXHIBIT 10.44 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. THIRD AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT BETWEEN AMYLIN PHARMACEUTICALS, INC. AND WOCKHARDT UK (HOLDINGS) LTD. This Third Amendment to the Amend
February 22, 2012	EX-4.10	AMENDED AND RESTATED PROMISSORY NOTE $165,000,000 San Diego, California November7, 2011 Amended and Restated Promissory Note EXEUTION VERSION Exhibit 4.10 THIS AMENDED AND RESTATED PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED. NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO AMYLIN, THAT SUCH RE
February 22, 2012	EX-4.7	SECURITY AGREEMENT AMYLIN PHARMACEUTICALS, INC., AMYLIN OHIO LLC, EACH OF THE OTHER GRANTORS PARTY HERETO ELI LILLY AND COMPANY November 7, 2011 TABLE OF CONTENTS PAGE ARTICLE I DEFINITIONS 1 1.1 General Definitions 1 1.2 Definitions; Interpretation Security Agreement Exhibit 4.7 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. EXECUTION VERSION SECURITY AGREEMENT among AMYLIN PHARMACEUTICALS, INC., AMYLIN OHIO LLC, EACH OF THE OTHER GRANTORS PARTY HERETO and ELI LILLY AND COMPANY November 7, 2011 TABLE OF CONTENTS PAGE ARTIC
February 22, 2012	EX-4.9	AMENDED AND RESTATED LOAN AGREEMENT AMYLIN PHARMACEUTICALS, INC. ELI LILLY AND COMPANY AMENDED AND RESTATED LOAN AGREEMENT Amended and Restated Loan Agreement Exhibit 4.9 EXECUTION VERSION AMENDED AND RESTATED LOAN AGREEMENT BETWEEN AMYLIN PHARMACEUTICALS, INC. AND ELI LILLY AND COMPANY AMENDED AND RESTATED LOAN AGREEMENT THIS AMENDED AND RESTATED LOAN AGREEMENT (the “Loan Agreement”) is made as of this 7th day of November, 2011 (the “Effective Date”) by and between AMYLIN PHARMACEUTICALS, INC., a Delaware corporation
February 22, 2012	EX-10.47	AMENDED AND RESTATED EXENATIDE ONCE WEEKLY SUPPLY AGREEMENT EX-10.47 13 d260205dex1047.htm AMENDED AND RESTATED EXENATIDE ONCE WEEKLY SUPPLY AGREEMENT Exhibit 10.47 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. EXECUTION VERSION AMENDED AND RESTATED EXENATIDE ONCE WEEKLY SUPPLY AGREEMENT This AMENDED AND RESTATED EXENATIDE ONCE WEEKLY S
February 22, 2012	EX-4.6	AMYLIN PHARMACEUTICALS, INC. SECURED PROMISSORY NOTE $1,200,000,000.00 November 7, 2011 Secured Promissory Note EXECUTION VERSION Exhibit 4.6 THIS SECURED PROMISSORY NOTE HAS NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”). NO SALE OR DISPOSITION MAY BE EFFECTED EXCEPT IN COMPLIANCE WITH RULE 144 UNDER SAID ACT OR AN EFFECTIVE REGISTRATION STATEMENT THERETO OR AN OPINION OF COUNSEL FOR THE HOLDER, SATISFACTORY TO AMYLIN THAT SUCH REGISTRATION A
February 22, 2012	EX-10.16	Summary Description of Named Executive Officer Oral At-Will Employment Agreement Summary Description of Named Executive Officer Oral At-Will Employment Agreement Exhibit 10.
February 22, 2012	EX-10.46	SETTLEMENT AND TERMINATION AGREEMENT by and between AMYLIN PHARMACEUTICALS, INC. ELI LILLY AND COMPANY November 7, 2011 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.1 Definitions 2 Section 1.2 Other Defined Terms 22 ARTICLE 2 TERMINATION Exhibit 10.46 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. EXECUTION VERSION SETTLEMENT AND TERMINATION AGREEMENT by and between AMYLIN PHARMACEUTICALS, INC. and ELI LILLY AND COMPANY November 7, 2011 TABLE OF CONTENTS Page ARTICLE 1 DEFINITIONS 2 Section 1.1 Definitions 2 Sec
February 22, 2012	10-K	Annual Report - FORM 10-K 10-K 1 d260205d10k.htm FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File No. 0-19
February 22, 2012	EX-10.42	C O N F I D E N T I A L EXENATIDE SUPPLY AGREEMENT Exenatide Supply Agreement EXHIBIT 10.42 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. FINAL C O N F I D E N T I A L EXENATIDE SUPPLY AGREEMENT THIS AGREEMENT effective July 31, 2007, the (“Effective Date”) is made by and between Amylin Ohio LLC., having a principal place of bu
February 22, 2012	EX-10.43	SUPPLY AGREEMENT ALKERMES, INC. AMYLIN OHIO LLC SUPPLY AGREEMENT Supply Agreement EXHIBIT 10.43 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2. SUPPLY AGREEMENT BETWEEN ALKERMES, INC. AND AMYLIN OHIO LLC SUPPLY AGREEMENT THIS SUPPLY AGREEMENT (“Agreement”) is made and entered into as of December 19, 2007 (the “Effective Date”) by and between A
February 22, 2012	EX-21.1	Subsidiaries of Amylin Pharmaceuticals, Inc. Subsidiaries of Registrant Exhibit 21.1 Subsidiaries of Amylin Pharmaceuticals, Inc. All of the following subsidiaries are 100% owned by Amylin Pharmaceuticals, Inc. Name State or Country of Incorporation or Organization Amylin Investments LLC Delaware Amylin Ohio LLC Delaware
February 22, 2012	EX-10.48	AMENDED AND RESTATED DEVICE AND FINISHED EQW PRODUCT MANUFACTURING AGREEMENT Amended and Restated Device and Finished EQW Product Manufacturing Agreement Exhibit 10.
February 14, 2012	SC 13G/A	AMLN / Amylin Pharmaceuticals Inc / WELLINGTON MANAGEMENT GROUP LLP - DISCLOSURE DOCUMENT Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 8)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032346108 (CUSIP Number) December 31, 2011 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 9, 2012	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers, Entry into a Material Definitive Agreement - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation
February 6, 2012	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation
February 6, 2012	EX-99.1	AMYLIN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL RESULTS Strategic Execution, Fiscal Discipline in 2011 Yield Non-GAAP Operating Income of $26 Million Press Release Exhibit 99.1 FOR IMMEDIATE RELEASE Contacts: Investors – Christine Everett-Zedelmayer Phone: (858) 458-8517 Email: [email protected] Investors – Michael York Phone: (858) 458-8602 Email: [email protected] Media – Alice Izzo Phone: (858) 642-7272 Email: [email protected] AMYLIN PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2011 FINANCIAL RESULTS Strategic E
January 30, 2012	EX-99.1	FDA Approves BYDUREON™ – The First and Only Once-Weekly Treatment for Type 2 Diabetes Provides Glycemic Control in a Once-Weekly Dose Press Release Exhibit 99.1 Media contacts: Amylin – Alice Izzo Phone: (858) 642-7272 Cell: (858) 232-9072 Email: [email protected] Alkermes – Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] FDA Approves BYDUREON™ – The First and Only Once-Weekly Treatment for Type 2 Diabetes Provides Glycemic Control in a Once-Weekly Dose SAN DIEGO and DUBLIN, I
January 30, 2012	8-K	Financial Statements and Exhibits, Other Events - FORM 8-K Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2012 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation
December 7, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2011 AMYLIN PHARMACEU FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 6, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation
November 8, 2011	EX-99.2	EX-99.2
November 8, 2011	8-K	Entry into a Material Definitive Agreement, Termination of a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 8, 2011 (November 7, 2011) AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Inc
November 8, 2011	EX-99.1	Lilly and Amylin Mutually Agree to End Diabetes Alliance and Transition Exenatide Responsibility to Amylin Agreement Will Resolve All Litigation Between the Two Companies Exhibit 99.1 Contacts: Amylin - Anne Erickson (Media) Michael York (Investors) Phone: (858) 754-4443 Phone: (858) 458-8602 Email: [email protected] Email: [email protected] Lilly - Tarra Ryker (Media) Phil Johnson (Investors) Phone: (317) 332-7502 Phone: (317) 655-6874 Email: [email protected] Email: [email protected] FOR IMMEDIATE RELEASE Lilly and Amylin Mutually Agree to
October 28, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d235704d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number
October 28, 2011	EX-10.1	AMENDMENT TO DEVICE DEVELOPMENT AND MANUFACTURING AGREEMENT EX-10.1 2 d235704dex101.htm AMENDMENT TO DEVICE DEVELOPMENT AND MANUFACTURING AGREEMENT Exhibit 10.1 Confidential AMENDMENT TO DEVICE DEVELOPMENT AND MANUFACTURING AGREEMENT THIS AMENDMENT (“Amendment”) is effective as of the 8th day of July, 2011 and is by and between AMYLIN PHARMACEUTICALS, INC., a Delaware corporation (“AMYLIN”), and ELI LILLY AND COMPANY, an Indiana corporation (“LILLY”). AMYL
October 20, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commis
October 20, 2011	EX-99.1	BYETTA® Approved for Use with Insulin Glargine in the U.S. Patients in Pivotal Study Achieved Better Glycemic Control Without Weight Gain or Increased Hypoglycemia Risk Versus Insulin Glargine Exhibit 99.1 Media contacts: Amylin ? Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly ? Kelley Murphy Phone: (317) 277-4607 Cell: (317) 701-4007 Email: [email protected] BYETTA? Approved for Use with Insulin Glargine in the U.S. Patients in Pivotal Study Achieved Better Glycemic Control Without Weight Gain or Increased Hypoglycemia Risk Versus Insulin
October 19, 2011	EX-99.1	AMYLIN PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS Non-GAAP Operating Income of $13 Million Amylin Well Positioned for Anticipated Launch of BYDUREONTM in Early 2012 Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS Non-GAAP Operating Income of $13 Million Amylin Well Positioned for Anticipated Launch of BYDUREONTM in Early 2012 San Diego, CA ? October 19, 2011 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2011. ? Total revenue was $175.0 millio
October 19, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2011 AMYLIN PHARMACEU Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation
August 8, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS, INC.
July 28, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 28, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commissio
July 28, 2011	EX-99.1	Media contacts: Amylin ? Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly ? Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes ? Rebecca Peterson Phone: (781) 609-6 Exhibit 99.1 Media contacts: Amylin ? Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly ? Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes ? Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] BYDUREON? REPLY SUBMITTED TO FDA New PDUFA Action Date Expected Within 14 D
July 26, 2011	EX-99.1	AMYLIN PHARMACEUTICALS REPORTS SECOND QUARTER FINANCIAL RESULTS Company Approaches Break-Even Operating Results with a 77% Improvement in Non-GAAP Operating Loss Compared to Same Period Last Year BYDUREON™ Approved for Use in Europe Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS SECOND QUARTER FINANCIAL RESULTS Company Approaches Break-Even Operating Results with a 77% Improvement in Non-GAAP Operating Loss Compared to Same Period Last Year BYDUREON? Approved for Use in Europe San Diego, CA ? July 26, 2011 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended J
July 26, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 26, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commissio
July 18, 2011	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AMYLIN PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AMYLIN PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 032346108 (CUSIP Number) July 6, 2011 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the
July 18, 2011	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi
July 8, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2011 AMYLIN PHARMACEUTICA Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 7, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (C
July 8, 2011	EX-99.1	Media contacts: Amylin – Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly – Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes – Rebecca Peterson Phone: (781) 609-6 EX-99.1 2 dex991.htm PRESS RELEASE Exhibit 99.1 Media contacts: Amylin – Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly – Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes – Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] Exenatide tQT Study Showed No Prolongati
July 5, 2011	EX-99.1	JOINT FILING AGREEMENT Exhibit 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, and that all subsequent amendments to this statement on Schedule 13G may be filed on behalf of each of the undersigned without the necessi
July 5, 2011	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AMYLIN PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* AMYLIN PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, Par Value $0.001 Per Share (Title of Class of Securities) 032346108 (CUSIP Number) June 23, 2011 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the
June 9, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 8, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commission
June 9, 2011	EX-99.1	Case 3:11-cv-01061-JLS -NLS SEALED Document 44 Filed 06/08/11 Page 1 of 4 1 2 3 4 5 6 UNITED STATES DISTRICT COURT 7 SOUTHERN DISTRICT OF CALIFORNIA 8 9 AMYLIN PHARMACEUTICALS, INC., CASE NO. 11-CV-1061 JLS (NLS) 10 Plaintiff, ORDER: (1) VACATING v Exhibit 99.1 Case 3:11-cv-01061-JLS -NLS SEALED Document 44 Filed 06/08/11 Page 1 of 4 1 2 3 4 5 6 UNITED STATES DISTRICT COURT 7 SOUTHERN DISTRICT OF CALIFORNIA 8 9 AMYLIN PHARMACEUTICALS, INC., CASE NO. 11-CV-1061 JLS (NLS) 10 Plaintiff, ORDER: (1) VACATING vs. TEMPORARY RESTRAINING 11 ORDER; (2) DENYING PLAINTIFF AMYLIN 12 PHARMACEUTICALS, INC.?S ELI LILLY AND COMPANY, MOTION FOR PRELIMINARY
May 26, 2011	EX-99.1	Case 3:11-cv-01061-JLS-NLS SEALED Document 14 Filed 05/23/11 Page 1 of 6 Order of the U.S. District Court Dated May 23, 2011 Exhibit 99.1 Case 3:11-cv-01061-JLS-NLS SEALED Document 14 Filed 05/23/11 Page 1 of 6 UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF CALIFORNIA AMYLIN PHARMACEUTICALS, INC., Plaintiff, vs. ELI LILLY AND COMPANY, Defendant. CASE NO. 11CV1061 JLS (NLS) ORDER 1) GRANTING IN PART PLAINTIFF’S MOTION FOR TEMPORARY RESTRAINING ORDER AND 2) SETTING
May 26, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 26, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commission
May 25, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2011 AMYLIN PHARMACEUTICA Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 24, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (C
May 23, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2011 Amylin Pharmaceutica Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 8-K Current Report Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 23, 2011 Amylin Pharmaceuticals, Inc. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or other jurisdiction of incorporation) (C
May 17, 2011	EX-99.1	AMYLIN PHARMACEUTICALS FILES SUIT AGAINST ELI LILLY Complaint Alleges Anticompetitive Activity and Breach of Strategic Alliance Agreements Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS FILES SUIT AGAINST ELI LILLY Complaint Alleges Anticompetitive Activity and Breach of Strategic Alliance Agreements San Diego, CA ? May 16, 2011 ? Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN) (?Amylin? or ?the Company?) today announced that it has filed a lawsuit against Eli Lilly and Company (NYSE: LLY) (?Lilly?) in the United States Distri
May 17, 2011	8-K	Financial Statements and Exhibits, Other Events 8-K 1 d8k.htm FORM 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 16, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Inc
May 5, 2011	EX-10.2	AMYLIN PHARMACEUTICALS, INC. 2003 NON-EMPLOYEE DIRECTORS? EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.2 AMYLIN PHARMACEUTICALS, INC. 2003 NON-EMPLOYEE DIRECTORS? EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Pursuant to the Restricted Stock Unit Award Grant Notice (the ?Grant Notice?) and this Restricted Stock Unit Award Agreement (the ?Agreement?) (collectively, the ?Award?) and in consideration of your services rendered or to be rendered, as applicable, Amylin Pharmaceut
May 5, 2011	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 d10q.htm FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2011 OR ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 A
May 5, 2011	EX-10.4	[Amylin Letterhead] ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(b)(4) and 240.24b-2 Exhibit 10.4 [Amylin Letterhead] February 14, 2011 Mallinckrodt Inc 675 McDonnell Blvd. St. Louis, Missouri 63134 Attn: Tim Nieters Re: Exenatide Manufacturing Agreement between Amylin Pharmaceuticals, Inc. (?Amylin?) and Mallinckrodt Inc. (?Mallinckrodt?) effective October 1, 2003,
May 5, 2011	EX-10.1	AMYLIN PHARMACEUTICALS, INC. 2003 NON-EMPLOYEE DIRECTORS’ EQUITY INCENTIVE PLAN ADOPTED APRIL 2, 2003 APPROVED BY STOCKHOLDERS MAY 14, 2003 ORIGINAL EFFECTIVE DATE: APRIL 2, 2003 AMENDED BY THE BOARD: MARCH 16, 2009 LAST AMENDED BY THE BOARD: MARCH 1 Exhibit 10.1 AMYLIN PHARMACEUTICALS, INC. 2003 NON-EMPLOYEE DIRECTORS? EQUITY INCENTIVE PLAN ADOPTED APRIL 2, 2003 APPROVED BY STOCKHOLDERS MAY 14, 2003 ORIGINAL EFFECTIVE DATE: APRIL 2, 2003 AMENDED BY THE BOARD: MARCH 16, 2009 LAST AMENDED BY THE BOARD: MARCH 1, 2011 1. PURPOSES AND RELATIONSHIP WITH THE COMPANY?S 2009 EQUITY INCENTIVE PLAN. (a) Eligible Award Recipients. The persons eligible fo
May 5, 2011	EX-10.3	AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.3 AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Pursuant to the Restricted Stock Unit Award Grant Notice (the ?Grant Notice?) and this Restricted Stock Unit Award Agreement (the ?Agreement?) (collectively, the ?Award?) and in consideration of your services rendered or to be rendered, as applicable, Amylin Pharmaceuticals, Inc. (the ?Compan
April 18, 2011	EX-99.1	AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS Operational Efficiencies Drove 10% Expense Reduction, 4% Gross Margin Improvement BYDUREON™ Recommended for Approval in Europe Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS Operational Efficiencies Drove 10% Expense Reduction, 4% Gross Margin Improvement BYDUREON? Recommended for Approval in Europe San Diego, CA ? April 18, 2011 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended March 31, 2011. The Company reported total
April 18, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2011 AMYLIN PHARMACEUTI Form 8-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 18, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation)
April 13, 2011	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Definitive Proxy Statement UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
April 13, 2011	DEFA14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Notice and Access Card UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 4, 2011	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2011 AMYLIN PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 1, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File Numb
March 3, 2011	8-K	Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commissio
March 3, 2011	EX-99.1	DURATION-6 Top-Line Study Results Announced Exhibit 99.1 Media contacts: Amylin ? Alice Izzo Phone: (858) 642-7272 Cell: (858) 232-9072 Email: [email protected] Lilly ? Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes ? Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] DURATION-6 Top-Line Study Results Announced SAN DIEGO, INDIANAPOLIS and WALTHAM,
February 25, 2011	EX-10.27	________________________________________________ Amylin Pharmaceuticals, Inc. 2001 Non-Qualified Deferred Compensation Plan Exhibit 10.27 Amylin Pharmaceuticals, Inc. 2001 Non-Qualified Deferred Compensation Plan November 15, 2010 TABLE OF CONTENTS PREAMBLE ARTICLE 1 ? GENERAL 1.1 Plan 1.2 Effective Dates 1.3 Amounts Not Subject to Code Section 409A ARTICLE 2 ? DEFINITIONS 2.1 Account 2.2 Account Balance Plan 2.3 Administrator 2.4 Adoption Agreement 2.5 Base Salary 2.6 Beneficiary 2.7 Board or Board of Directors 2.8 Bo
February 25, 2011	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Use these links to rapidly review the document PART IV TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
February 25, 2011	EX-10.20	Summary Description of Named Executive Officer Oral At-Will Employment Agreement Exhibit 10.20 Summary Description of Named Executive Officer Oral At-Will Employment Agreement With the exception of Daniel M. Bradbury, our President and Chief Executive Officer, with whom we have a written employment agreement, we maintain oral at-will employment relationships with each of our other currently-serving named executive officers: Mark G. Foletta, Mark J. Gergen, Orville G. Kolterman
February 25, 2011	EX-10.52	SECOND AMENDMENT TO MASTER SERVICES AGREEMENT AMYLIN PHARMACEUTICALS, INC. WOCKHARDT UK (HOLDINGS) LTD. Exhibit 10.52 ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R. ?? 200.80(b)(4) and 240.24b-2 SECOND AMENDMENT TO MASTER SERVICES AGREEMENT BETWEEN AMYLIN PHARMACEUTICALS, INC. AND WOCKHARDT UK (HOLDINGS) LTD. This Second Amendment to the Amended and Restated Commercial Supply Agreement (this ?Second Amendment?) is made as of November 1, 2010 (?Effective Date?),
February 25, 2011	EX-21.1	Subsidiaries of Amylin Pharmaceuticals, Inc. Exhibit 21.1 Subsidiaries of Amylin Pharmaceuticals, Inc. The following subsidiaries are 100% owned by Amylin Pharmaceuticals, Inc. Name State or Country of Incorporation or Organization Amylin Investments LLC Delaware Amylin Ohio LLC Delaware
February 25, 2011	EX-10.51	AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.51 AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Pursuant to the Restricted Stock Unit Award Grant Notice (the ?Grant Notice?) and this Restricted Stock Unit Award Agreement (the ?Agreement?) (collectively, the ?Award?) and in consideration of your services rendered or to be rendered, as applicable, Amylin Pharmaceuticals, Inc. (the ?Compa
February 14, 2011	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 7)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032346108 (CUSIP Number) December 31, 2010 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
January 26, 2011	EX-99.1	AMYLIN PHARMACEUTICALS REPORTS 2010 FINANCIAL RESULTS 2010 Non-GAAP Operating Loss Improves by 93% to $4 Million Compared to 2009 Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS 2010 FINANCIAL RESULTS 2010 Non-GAAP Operating Loss Improves by 93% to $4 Million Compared to 2009 San Diego, CA ? January 26, 2011 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter and year ended December 31, 2010. The Company reported total revenue of $174.2 million for the quarter ende
January 26, 2011	8-K	Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2011 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commis
December 3, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2010 AMYLIN PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 30, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File
November 8, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q 10-Q 1 a10-17237110q.htm 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0
November 8, 2010	EX-10.1	AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT FOR EXENATIDE Exhibit 10.1 CONFIDENTIAL AMENDMENT TO COMMERCIAL SUPPLY AGREEMENT FOR EXENATIDE THIS AMENDMENT (?Amendment?) is effective as of April 29, 2010 and is by and between AMYLIN PHARMACEUTICALS, INC., a Delaware corporation (?Amylin?), having a place of business at 9360 Towne Centre Drive, San Diego, California 92121 and BACHEM, INC., a California corporation (?Bachem?), with an address of 3132 Kashiwa
November 8, 2010	EX-10.2	THIRD Amendment to Commercial Supply Agreement for Exenatide ***Text Omitted and Filed Separately Confidential Treatment Requested Under 17 C.F.R ?? 200.80(b)(4) And 240.24b-2 Exhibit 10.2 CONFIDENTIAL THIRD Amendment to Commercial Supply Agreement for Exenatide THIS THIRD AMENDMENT (?Amendment?) is effective as of September 20, 2010 and is by and between AMYLIN PHARMACEUTICALS, INC., a Delaware corporation (?Amylin?), having a place of business at 9360 Tow
November 4, 2010	EX-99.1	AMYLIN PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS Year-to-Date Non-GAAP Operating Loss of $27.3 million improves by 34% compared to 2009 Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS Year-to-Date Non-GAAP Operating Loss of $27.3 million improves by 34% compared to 2009 San Diego, November 4, 2010 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarter ended September 30, 2010. The Company reported total revenue of $156.1 million for the third
November 4, 2010	8-K	Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 4, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File N
October 21, 2010	EX-99.3	Amylin Pharmaceuticals, Inc. Conference Call Held on October 19, 2010 Exhibit 99.3 Amylin Pharmaceuticals, Inc. Conference Call Held on October 19, 2010 PRESENTATION Operator Welcome to the Amylin Update. At this time, participants are in a listen-only mode until the question-and-answer session begins. (Operator Instructions.) This conference is being recorded, so if you have any objections, you may disconnect at this time. And I would like to introduce your host, M
October 21, 2010	EX-99.2	AMYLIN, LILLY AND ALKERMES ANNOUNCE RECEIPT OF COMPLETE RESPONSE LETTER FROM FDA FOR BYDUREON™ Exhibit 99.2 Media contacts: Amylin ? Alice Izzo Phone: (858) 642-7272 Cell: (858) 232-9072 Email: [email protected] Lilly ? Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes ? Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] AMYLIN, LILLY AND ALKERMES ANNOUNCE RECEIPT OF COMPLETE RESPONSE LETTER FROM FDA
October 21, 2010	8-K	Other Events, Results of Operations and Financial Condition, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 19, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File N
October 21, 2010	EX-99.1	AMYLIN PHARMACEUTICALS ANNOUNCES THIRD QUARTER PRODUCT REVENUES; QUARTERLY UPDATE CONFERENCE CALL CANCELED Exhibit 99.1 FOR IMMEDIATE RELEASE Media contact: Alice Izzo Phone: (858) 642-7272 Email: [email protected] Investor Contact: Michael York Phone: (858) 458-8602 Email: [email protected] AMYLIN PHARMACEUTICALS ANNOUNCES THIRD QUARTER PRODUCT REVENUES; QUARTERLY UPDATE CONFERENCE CALL CANCELED SAN DIEGO, October 19, 2010 ? Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today announced that un
August 5, 2010	EX-10.1	[on Amylin Letterhead] Exhibit 10.1 [on Amylin Letterhead] July 13, 2006 Alkermes Controlled Therapeutics Inc. II 88 Sidney Street Cambridge, MA 02139 Attn: Mike Landine Dear Mr. Landine: Amylin Pharmaceuticals, Inc. (?Amylin?) and Alkermes Controlled Therapeutics Inc. II (?ACT II?) are parties to a Development and License Agreement effective as of May 15, 2000, as amended (the ?Development and License Agreement?), purs
August 5, 2010	10-Q	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS, INC.
July 21, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2010 AMYLIN PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 21, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commissio
July 21, 2010	EX-99.1	AMYLIN PHARMACEUTICALS REPORTS SECOND QUARTER FINANCIAL RESULTS Year-to-Date Non-GAAP Operating Loss of $11.2 Million Improves by 74% Compared to 2009 Data Presented at ADA Further Demonstrated Safety and Efficacy Profiles of BYDUREON and BYETTA Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS SECOND QUARTER FINANCIAL RESULTS Year-to-Date Non-GAAP Operating Loss of $11.2 Million Improves by 74% Compared to 2009 Data Presented at ADA Further Demonstrated Safety and Efficacy Profiles of BYDUREON and BYETTA San Diego, CA — July 21, 2010 — Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the qu
June 15, 2010	EX-99.1	DURATION-4 Study Results: BYDUREON™ Efficacy and Tolerability Profile Extended to Monotherapy Treatment Exhibit 99.1 Media contacts: Amylin ? Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly ? Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes ? Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 & nbsp; Email: [email protected] DURATION-4 Study Results: BYDUREON? Efficacy and Tolerability Profi
June 15, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2010 AMYLIN PHARMACEUTIC UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of (Commission File Number)
June 9, 2010	EX-24	EX-24 POWER OF ATTORNEY Known all by these presents, that the undersigned hereby authorizes Daniel M.
June 9, 2010	EX-24	EX-24 POWER OF ATTORNEY Known all by these presents, that the undersigned hereby authorizes Daniel M.
May 6, 2010	EX-10.3	[Amylin Letterhead] EXHIBIT 10.3 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 [Amylin Letterhead] February 11, 2010 Baxter Pharmaceutical Solutions LLC 927 South Curry Pike Bloomington, Indiana 47403 Attn: Brik Eyre Re: Commercial Supply Agreement between Baxter Pharmaceutical Solutions LLC (“Baxt
May 6, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2010 AMYLIN PHARMACEUTICAL UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File Number
May 6, 2010	EX-10.2	[Amylin Letterhead] EXHIBIT 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 [Amylin Letterhead] January 8, 2010 Mallinckrodt Inc 675 McDonnell Blvd. St. Louis, Missouri 63134 Attn: Tom Palmer Re: Exenatide Manufacturing Agreement between Amylin Pharmaceuticals, Inc. (“Amylin”) and Mallinckrodt I
May 6, 2010	10-Q	Research and Development Expenses Research and development costs are expensed as incurred and include salaries and bonuses, benefits, non-cash stock-based compensation, license fees, milestone payments due under license agreements, costs paid to thi Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2010 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS, INC
May 6, 2010	EX-99.1	BYDUREON™ FDA REVIEW TIMELINE SET WITH PDUFA ACTION DATE OF OCTOBER 22, 2010 Exhibit 99.1 Media contacts: Amylin – Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly – Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes – Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] BYDUREON™ FDA REVIEW TIMELINE SET WITH PDUFA ACTION DATE OF OCTOBER 22, 201
May 6, 2010	EX-10.1	AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Exhibit 10.1 AMYLIN PHARMACEUTICALS, INC. 2009 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AWARD AGREEMENT Pursuant to the Restricted Stock Unit Award Grant Notice (the “Grant Notice”) and this Restricted Stock Unit Award Agreement (the “Agreement”) (collectively, the “Award”) and in consideration of your services rendered or to be rendered, as applicable, Amylin Pharmaceuticals, Inc. (the “Compan
April 30, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2010 AMYLIN PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 29, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File Num
April 19, 2010	EX-99.1	AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS Exhibit 99.1 FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS FIRST QUARTER FINANCIAL RESULTS Non-GAAP Operating Loss Improves by 81% to $3.8 Million Compared to the First Quarter of 2009 BYDUREON Response to FDA Will Be Submitted This Week BYDUREON Marketing Authorization Application Submitted to the European Medicines Agency San Diego, CA — April 19, 2010 — Amylin Pharmaceuticals, Inc. (Nasd
April 19, 2010	10-K/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT NO. 1 10-K/A 1 a10-8253110ka.htm 10-K/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A AMENDMENT NO. 1 x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commi
April 19, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2010 AMYLIN PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 19, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File Num
March 19, 2010	DEF 14A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) QuickLinks - Click here to rapidly navigate through this document UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.
March 19, 2010	DEFA14A	UNITED STATES UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) o Defin
March 15, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2010 AMYLIN PHARMACEUTI UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 15, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File Num
March 15, 2010	EX-99.1	AMYLIN, LILLY AND ALKERMES RECEIVE COMPLETE RESPONSE LETTER FROM FDA FOR EXENATIDE ONCE WEEKLY SUBMISSION BYDUREON™ (exenatide for extended-release injectable suspension) Proposed Name Exhibit 99.1 Media contacts: Amylin — Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly — Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes — Rebecca Peterson Phone: (781) 609-6378 Cell: (617) 899-2447 Email: [email protected] AMYLIN, LILLY AND ALKERMES RECEIVE COMPLETE RESPONSE LETTER FROM FDA FOR EX
March 5, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2010 AMYLIN PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commis
February 26, 2010	EX-10.10	AMYLIN PHARMACEUTICALS, INC. 2003 NON-EMPLOYEE DIRECTORS? STOCK OPTION PLAN STOCK OPTION AGREEMENT (NONSTATUTORY STOCK OPTION) Exhibit 10.10 AMYLIN PHARMACEUTICALS, INC. 2003 NON-EMPLOYEE DIRECTORS’ STOCK OPTION PLAN STOCK OPTION AGREEMENT (NONSTATUTORY STOCK OPTION) Pursuant to your Stock Option Grant Notice (“Grant Notice”) and this Stock Option Agreement, Amylin Pharmaceuticals, Inc. (the “Company”) has granted you an option pursuant to the Company’s 2003 Non-Employee Directors’ Stock Option Plan (the “Plan”) to purcha
February 26, 2010	EX-10.53	[AMYLIN LETTERHEAD] EXHIBIT 10.53 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 [AMYLIN LETTERHEAD] October 30, 2009 Takeda Pharmaceutical Company Limited 1-1, Doshomachi 4-chome, Chuo-ku Osaka 540-8645, Japan Attention: Mr. Yasuchika Hasegawa, President & CEO Re: License, Development and Commercia
February 26, 2010	EX-21.1	Subsidiaries of Amylin Pharmaceuticals, Inc. Exhibit 21.1 Subsidiaries of Amylin Pharmaceuticals, Inc. All of the following subsidiaries are 100% owned by Amylin Pharmaceuticals, Inc. Name State or Country of Incorporation or Organization Amylin Investments LLC Delaware Amylin Ohio LLC Delaware
February 26, 2010	EX-10.52	LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN AMYLIN PHARMACEUTICALS, INC. TAKEDA PHARMACEUTICAL COMPANY LIMITED DATED: OCTOBER 30, 2009 EXHIBIT 10.52 *Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 LICENSE, DEVELOPMENT AND COMMERCIALIZATION AGREEMENT BY AND BETWEEN AMYLIN PHARMACEUTICALS, INC. AND TAKEDA PHARMACEUTICAL COMPANY LIMITED DATED: OCTOBER 30, 2009 *Text Omitted and Filed Separately with the Securities
February 26, 2010	10-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K 10-K 1 a2196628z10-k.htm 10-K Use these links to rapidly review the document TABLE OF CONTENTS UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For The Fiscal Year Ended December 31, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 193
February 26, 2010	EX-10.26	Summary Description of Named Executive Officer Oral At-Will Employment Agreement Exhibit 10.26 Summary Description of Named Executive Officer Oral At-Will Employment Agreement With the exception of Daniel M. Bradbury, our President and Chief Executive Officer, with whom we have a written employment agreement, we maintain oral at-will employment relationships with each of our other currently-serving named executive officers: Mark G. Foletta, Orville G. Kolterman, M.D., Marcea B
February 26, 2010	EX-18	January 21, 2010 Exhibit 18 January 21, 2010 Board of Directors and Management Amylin Pharmaceuticals Dear Members of the Board of Directors and Management: Note 1 of the Notes to the Consolidated Financial Statements of Amylin Pharmaceuticals, Inc.
February 26, 2010	EX-10.54	THIRD AMENDMENT Exhibit 10.54 THIRD AMENDMENT THIS THIRD AMENDMENT, dated as of December 18, 2009 (this “Amendment”), among AMYLIN PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), each of the Company’s subsidiaries listed on the signature pages hereto (collectively, together with the Company, the “Borrowers” and each a “Borrower”), the Lenders (as defined below) party hereto, and BANK OF AMERICA, N.
February 16, 2010	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 CUSIP No. 032346108 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032346108 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rul
February 12, 2010	SC 13G/A	SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 6)* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032346108 (CUSIP Number) December 31, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which
February 5, 2010	8-K	Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 2, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of Incorporation) (Commis
January 27, 2010	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2010 AMYLIN PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2010 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File N
January 27, 2010	EX-99.1	AMYLIN PHARMACEUTICALS REPORTS 2009 FINANCIAL RESULTS Exhibit 99.1 Amylin Pharmaceuticals, Inc. 9360 Towne Centre Drive San Diego, CA 92121 USA Tel (858) 552 2200 Fax (858) 552 2212 www.amylin.com FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS 2009 FINANCIAL RESULTS 2009 Non-GAAP Operating Loss Improves by 57% Over 2008 San Diego, CA — January 27, 2010 — Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN) today reported financial results for the quarte
December 15, 2009	EX-99.1	1 Exhibit 99.1 Media contacts: Amylin ? Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly ? Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] Alkermes ? Rebecca Peterson Phone: (617) 583-6378 Cell: (617) 899-2447 Email: [email protected] Exenatide Once Weekly Provided Superior Glucose Control Compared to BYETTA?
December 15, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2009 AMYLIN PHARMACE UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 15, 2009 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 0-19700 33-0266089 (State or Other Jurisdiction of (Commission File Numb
November 5, 2009	10-Q	Research and Development Expenses Research and development costs are expensed as incurred and include salaries and bonuses, benefits, non-cash stock-based compensation, license fees, milestones under license agreements and costs paid to third-party Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS,
November 2, 2009	EX-99.1	Media contacts: Amylin – Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly – Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] BYETTA Approved for Expanded Use as First-Line Exhibit 99.1 Media contacts: Amylin – Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly – Kindra Strupp Phone: (317) 277-5170 Cell: (317) 554-9577 Email: [email protected] BYETTA Approved for Expanded Use as First-Line Treatment for Type 2 Diabetes Prescribing Information Also Includes Updated Safety Information SAN DIEGO and INDIANAPOLIS – Oct. 30, 200
November 2, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2009 AMYLIN PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2009 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File N
November 2, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2009 AMYLIN PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 30, 2009 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File N
October 20, 2009	8-K	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2009 AMYLIN PHARMACEU UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K Current Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 20, 2009 AMYLIN PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware (State or Other Jurisdiction of Incorporation) 0-19700 (Commission File N
October 20, 2009	EX-99.1	EX-99.1 Exhibit 99.1 Amylin Pharmaceuticals, Inc. 9360 Towne Centre Drive San Diego, CA 92121 USA Tel (858) 552 2200 Fax (858) 552 2212 www.amylin.com FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS THIRD QUARTER FINANCIAL RESULTS Non-GAAP Operating Loss Improves by 64% to $41.6 Million in First Nine Months of 2009 Compared to Same Period in 2008 San Diego, CA ? October 20, 2009 ? Amylin Pharmaceutic
October 9, 2009	SC 13G/A	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC 1745 Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
October 2, 2009	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC Page 1 of 7 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB APPROVAL OMB Number: 3235-0145 Expires: December 31, 2009 Estimated average burden hours per response 10.4 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 032346108 (CUSIP Number) September 24,
September 18, 2009	SC 13G	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ___________)* UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Amylin Pharmaceuticals, Inc. (Name of Issuer) Common Stock, $.001 par value (Title of Class of Securities) 032346108 (CUSIP Number) September 17, 2009 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule
August 7, 2009	EX-10.3	SECOND AMENDMENT, CONSENT AND WAIVER Exhibit 10.3 SECOND AMENDMENT, CONSENT AND WAIVER THIS SECOND AMENDMENT, CONSENT AND WAIVER dated as of May 6, 2009 (this ?Amendment?), among AMYLIN PHARMACEUTICALS, INC., a Delaware corporation (the ?Company?), each of the Company?s subsidiaries listed on the signature pages hereto (collectively, together with the Company, the ?Borrowers? and each a ?Borrower?), the Lenders (as defined below) par
August 7, 2009	EX-10.4	The SCWT will meet at such other times as are agreed to by the Parties, but no less than once each [*]. Such meetings may be in-person, via video conference, or via telephone conference. At least five (5) business days prior to each SCWT meeting, e EXHIBIT 10.4 *Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 EXENATIDE ONCE WEEKLY PEN SUPPLY AGREEMENT This EXENATIDE ONCE WEEKLY PEN SUPPLY AGREEMENT (“Agreement”) is entered into as of May 11, 2009 (the “Effective Date”), by and between Amylin Pharmaceuticals, Inc. (“Amylin”),
August 7, 2009	EX-10.1	Re: Collaboration Agreement between Eli Lilly and Company (?Lilly?) and Amylin Pharmaceuticals, Inc. (?Amylin?), dated September 19, 2002, as amended to date (the ?Collaboration Agreement?) Exhibit 10.1 April 09, 2009 Eli Lilly and Company Lilly Corporate Center Indianapolis, IN 46285 Attention: Bryce Carmine Re: Collaboration Agreement between Eli Lilly and Company (“Lilly”) and Amylin Pharmaceuticals, Inc. (“Amylin”), dated September 19, 2002, as amended to date (the “Collaboration Agreement”) Dear Bryce: This letter confirms our understanding with respect to certain amendments to
August 7, 2009	10-Q	Research and Development Expenses Research and development costs are expensed as incurred and include salaries and bonuses, benefits, non-cash stock-based compensation, license fees, milestones under license agreements and costs paid to third-party Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2009 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 0-19700 AMYLIN PHARMACEUTICALS, INC.
August 7, 2009	EX-10.2	COST ALLOCATION AGREEMENT EXHIBIT 10.2 ***Text Omitted and Filed Separately with the Securities and Exchange Commission. Confidential Treatment Requested Under 17 C.F.R. Sections 200.80(b)(4) and 240.24b-2 COST ALLOCATION AGREEMENT This COST ALLOCATION AGREEMENT (this “Agreement”) is entered into and effective as of May 4, 2009 by and between ELI LILLY AND COMPANY, a corporation organized and existing under the laws of the
July 29, 2009	CORRESP	********** July 29, 2009 VIA FEDEX AND EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.
July 21, 2009	EX-99.1	AMYLIN PHARMACEUTICALS REPORTS SECOND QUARTER FINANCIAL RESULTS Exhibit 99.1 Amylin Pharmaceuticals, Inc. 9360 Towne Centre Drive San Diego, CA 92121 USA Tel (858) 552 2200 Fax (858) 552 2212 www.amylin.com FOR IMMEDIATE RELEASE AMYLIN PHARMACEUTICALS REPORTS SECOND QUARTER FINANCIAL RESULTS Non-GAAP Operating Loss Improves by 50% to $42.2 Million in First Half of 2009 Compared to First Half of 2008 New Drug Application for Exenatide Once Weekly Submitted and
July 21, 2009	EX-99.2	Significant Reductions in Weight and Fewer Reports of Hypoglycemia Compared to Lantus Also Observed Exhibit 99.2 Media contacts: Amylin – Anne Erickson Phone: (858) 754-4443 Cell: (858) 349-3195 Email: [email protected] Lilly – Tim Coulom Phone: (317) 655-2998 Cell: (317) 544-9757 Email: [email protected] Alkermes – Rebecca Peterson Phone: (617) 583-6378 Cell: (617) 899-2447 Email: [email protected] Exenatide Once Weekly Provided Superior Glucose Control Compared To Lan

AMLN / Amylin Pharmaceuticals Inc - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

Mga Batayang Estadistika

SEC Filings

SEC Filings (Chronological Order)